Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse

D. A. Goodwin, C. F. Meares, M. J. McCall, M. K. Haseman, M. McTigue, C. I. Diamanti, W. Chaovapong

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95%, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.

Original languageEnglish (US)
Pages (from-to)493-502
Number of pages10
JournalJournal of Nuclear Medicine
Volume26
Issue number5
StatePublished - 1985
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Goodwin, D. A., Meares, C. F., McCall, M. J., Haseman, M. K., McTigue, M., Diamanti, C. I., & Chaovapong, W. (1985). Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. Journal of Nuclear Medicine, 26(5), 493-502.